<DOC>
	<DOC>NCT00447369</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of pregabalin in comparison with sodium valproate in migraine prevention with a randomized blinded crossover study.</brief_summary>
	<brief_title>Efficacy of Pregabalin in Migraine Prevention</brief_title>
	<detailed_description>The anticonvulsants are effective in the treatment of migraine prevention. The sodium valproate has demonstrated to be effective as monotherapy for migraine prevention in placebo-controlled trials. Besides, other new drugs like gabapentin have been used in the prevention of migraine with a good level of evidence. The pregabalin is an anticonvulsant that has not been proved to use in migraine prevention and it has a similar action mechanisms of the gabapentin. The purpose of this study is the comparison of the effect of pregabalin and sodium valproate in migraine prevention in a randomized blinded crossover study.</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Migraine with or without aura according to International Headache Society (IHS) criteria for at least 6 months before study entry. Frequency of 3 or more headache attacks per month and less than 15 headache attacks per month. Available for followup at least 9 months. Exclusion criteria: Patients with headache others than migraine. Patients failed to respond to more than 2 adequate previous regimen of migrainepreventive medications. Prophylactic drugs for migraine 12 weeks before randomization. Onset of migraine occurred after 50 years. Hypersensitivity to pregabalin or sodium valproate.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>pregabalin</keyword>
	<keyword>Valproic acid</keyword>
	<keyword>migraine</keyword>
	<keyword>prophylaxis</keyword>
	<keyword>prevention</keyword>
	<keyword>treatment</keyword>
</DOC>